Drug Profile
Cal 1
Alternative Names: Autologous CD34+ Haematopoietic Stem/Progenitor Cells + CD4+ T Lymphocytes Transduced with LVsh5/C46 - Calimmune; Cal 1 therapy; Cal 1-modified HSPC; Cal 1-transduced haematopoietic stem progenitor cells; Cal-1; Cal-1-Calimmune; Cal-1-transduced-haematopoietic-stem-progenitor-cells-Calimmune; Dual Anti-HIV Gene Transfer Construct; LVsh5/C46-transduced-HSPC; LVsh5C46; LVsh5C46-transduced-HSPCLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator Calimmune
- Developer Assistance Publique Hopitaux de Paris; Calimmune
- Class Antivirals; Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for HIV-1 infections (Prevention) in USA (IV)
- 23 Mar 2023 No development reported - Phase-I/II for HIV-1 infections in France (IV)
- 23 Mar 2023 No development reported - Phase-I/II for HIV-1 infections in USA (IV)